Eyestem is a startup founded in 2018 based in India. Its most recent tracked round is Series B. Brouky records 1 investor associated with the company.
Eyestem develops scalable cell replacement therapies using induced pluripotent stem cells to treat incurable diseases, with a focus on replacing damaged photoreceptor cells in the eye to restore vision for conditions like dry age-related macular degeneration.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.